Executive Director of Key Lab of Metabolic Disease, Xiamen City
Zhongxian Lu received his Ph.D degree in Physiology from China Agricultural University, Beijing, China. He had postdoctoral training with Dr. Yeguang Chen at University of California Riverside, USA, from 2000-2002. Then, Dr. Lu moved to University of California Irvine and worked as a postdoctoral fellow from 2002-2006, and later as an assistant project scientist at Dr. Bogi Andersen’s Lab. In 2007, Dr. Lu was employed as a professor in Institute for Biomedical Research & School of Pharmaceutical Sciences, Xiamen University, China.
The novel molecular therapeutic target is hope for some complex diseases, such as cancer, diabetes, obesity, etc. Our research focuses on the identification of original molecular therapeutic targets by discovering the regulation of important proteins (such as Shp2, Gab2, AGR2) on the metabolic disease, cancer, reproductive system diseases with transgenic animal model and disease animal model. We also screen and develop potential new drugs against these targets from nature product and chemical molecule.
Awards and Honors:
2012.4, “Qingyuan” Research and Teaching Award from Xiamen University,
2011.6, New Century Excellent Talents in Fujian Province from Education Department of Fujian Province
2004.4, Postdoctoral fellowship award from Department of Defense Breast Cancer Research Program (BRCP).
Wenjie Liu Assistant Professor,
Ph.D. China Agricultural University, China
Selected Publications:（last 5 years）
Yingpu Tian, Baozhen Chen, Pengfei Guan, Yujia Kang and Zhongxian Lu*. A prognosis classifier for breast cancer based on conserved gene regulation between mammary gland development and tumorigenesis: a multiscale statistical model. Plos One, 2013; 8(4):e60131. doi: 10.1371 journal.pone.0060131. Epub 2013 Apr 2
Jie Wu, Chi Wang, Xilan Li, Yanling Song, Wei Wang, Cong Li, Jia Hu, Zhi Zhu, Jiuxing Li,Weiyun Zhang, Zhongxian Lu* and Chaoyong James Yang*. Identification, Characterization and Application of aG-Quadruplex Structured DNA Aptamer against Cancer Biomarker Protein Anterior Gradient Homolog 2. Plos One, 2012, 7(9):e46393. doi: 10.1371
Dongping Liu#, Guiping Kong#, QuanCheng Chen, Guanghui Wang, Jie Li, Yang Xu, Ting lin, Yingpu Tian, Xiaokun Zhang, Xinsheng Yao, Gensheng Feng, Zhongxian Lu* and Haifeng Chen*. Fatty acids as natural specific inhibitors of the proto-oncogenic protein Shp2. Bioorganic & Medicinal Chemistry Letters , 2011，6833-6837.
Jia Hu, Jie Wu, Cong Li, Ling Zhu, Weiyun Zhang, Guiping Kong，Zhongxian Lu*, Chaoyong Yang*. A G-aquadruplex aptamer inhibits the phosphatase activity of oncogenic protein shp2. Chembiochem, 2011, 12(3):424-30.
Yanyan Bu , Tao Shi , Minghui Meng , Guiping Kong, Yingpu Tian ,Quancheng Chen, Gensheng Feng, Xinsheng Yao, Haifeng Chen* and Zhongxian Lu*. A novel screening model for molecular drug for diabetes and obesity based on the tyrosine phosphatase Shp2. Bioorganic & Medicinal Chemistry Letters 2011，21(2): 874-878
Yingpu Tian, Ning Wang and Zhongxian Lu*. Repression of Lmo4 activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells. Clinical & Experimental Metastasis， 2010，27（7）：455-463
Email: Email: email@example.com